15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
by
Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA.
Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston ; the Department of Psychiatry, University of Texas, Southwestern Medical Center, Dallas ; the Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pa. ; the Department of Psychiatric Medicine, University of Virginia, Charlottesville ; the Neuroscience Education Institute, University of California, San Diego ; Bay Pointe Depression Clinic, New Baltimore, Mich. ; and Innovaa Research, Chapel Hill, N.C.
Prim Care Companion J Clin Psychiatry. 2005;7(3):106-113


ABSTRACT

Background: Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, a twice-daily sustained-release formulation followed in 1996, and, in August 2003, a once-daily extended-release formulation was introduced. On the 15th anniversary of its introduction, we undertook a review of the background/history, mechanism of action, formulations, and clinical profile of bupropion.Data Sources: Major efficacy trials and other reports were obtained and reviewed from MEDLINE searches, review of abstracts from professional meetings, and the bupropion SR manufacturer's databases. Searches of English-language articles were conducted from June 2003 through August 2004. No time limit was specified in the searches, which were conducted using the search terms bupropion, bupropion SR, and bupropion XL.Data Synthesis: Bupropion inhibits the re-uptake of norepinephrine and dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. Bupropion is an effective antidepressant with efficacy comparable to selective serotonin reuptake inhibitors and other antidepressants. It is well tolerated in short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, and dizziness are the most common adverse events. Seizure and allergic reactions are medically important adverse events associated with bupropion and are reported rarely. Among all the newer antidepressants in the United States, bupropion appears to have among the lowest incidence of sexual dysfunction, weight gain, and somnolence. Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents.Conclusion: Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.
SAD
Zyban
Bupropion.com
Drugs and reward
Bupropion and sex
The Coolidge Effect
Bupropion and REM
Bupropion overdose
Bupropion and mania
Bupropion and seizures
Bupropion and smoking
Bupropion and depression
Bupropion versus paroxetine
Bupropion and its metabolites
Bupropion for depressed bipolars
Bupropion used to augment SSRIs
Bupropion and the dopamine transporter
Bupropion and psychomotor performance
Bupropion SR for atopic dermatitis and psoriasis
Bupropion enhances pleasure for smokers who quit


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family